LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

3.63 -4.72

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.59

Max

3.85

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 50.102
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+222.83% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-107M 803M
Ankstesnė atidarymo kaina	8.35
Ankstesnė uždarymo kaina	3.63

Naujienos nuotaikos

By Acuity

50%

156 / 344 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-28 22:47; UTC

Uždarbis

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026-05-28 20:45; UTC

Uždarbis

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026-05-28 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-28 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026-05-28 23:31; UTC

Rinkos pokalbiai

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026-05-28 23:17; UTC

Rinkos pokalbiai

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026-05-28 23:02; UTC

Rinkos pokalbiai

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026-05-28 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026-05-28 21:12; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-28 21:00; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026-05-28 20:57; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:55; UTC

Uždarbis

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026-05-28 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-28 20:48; UTC

Karštos akcijos

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026-05-28 20:34; UTC

Uždarbis

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026-05-28 20:31; UTC

Uždarbis

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026-05-28 20:28; UTC

Uždarbis

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026-05-28 20:26; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Membership Fees $1.37B

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Net Sales $69.15B

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Same-Store Sales Up 9.8% >COST

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

222.83% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 222.83%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

156 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.